PDCD1 and esophageal squamous cell carcinoma: Tislelizumab + CT has not been directly compared with pembrolizumab + CT, nivolumab + CT or ipilimumab, or other PD-1 inhibitor–based immuno-oncology (IO) regimens for the 1L treatment of ESCC.